Encontrados 8 documentos, a visualizar página 1 de 1

Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, ...

Made available in DSpace on 2018-12-11T17:24:18Z (GMT). No. of bitstreams: 0 Previous issue date: 2018-07-01; Hospital Universitário Walter Cantídio - Universidade Federal do Ceará (HUWC UFC); Faculdade de Medicina de Botucatu da Universidade Estadual Paulista (FMB Unesp); Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM Unifesp); Hospital das Clínicas Faculdade de Medicina Universidade de ...

Part 2: Myelodysplastic syndromes – classification systems

Made available in DSpace on 2018-12-11T16:54:53Z (GMT). No. of bitstreams: 0 Previous issue date: 2018-07-01; Instituto Nacional de Ciência e Tecnologia do Sangue da Universidade Estadual de Campinas (Hemocentro Unicamp); Faculdade de Medicina de Botucatu da Universidade Estadual Paulista (FMB UNESP); Associação Médica Brasileira (AMB); Faculdade de Medicina de Botucatu da Universidade Estadual Paulista (FMB UN...

SIVA, a target of p53, is downregulated in myelodysplastic syndromes

Improving the differential diagnosis between myelodysplastic syndromes and reac...

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who ...

OBJECTIVE: To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib. METHODS: Bone marrow karyotyping and real-time quantitative polymerase chain reaction were performed at baseline and at 3, 6, 12...

Low educational level but not low income impairs the achievement of cytogenetic...

OBJECTIVES: In Brazil, imatinib mesylate is supplied as the first-line therapy for chronic myeloid leukemia in the chronic phase through the public universal healthcare program, Sistema Único de Saúde (SUS). We studied the socio-demographic factors that influenced therapy success in a population in the northeast region of Brazil. METHODS: Patients with chronic myeloid leukemia from the state of Piauí were treat...

Primary myelofibrosis: risk stratification by IPSS identifies patients with poo...

OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival. RESULTS: A V617F JAK2 mu...

Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with m...

INTRODUCTION: Myelodysplastic syndromes encompass a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, refractory cytopenia and a tendency to progress toward acute myeloid leukemia. The accumulation of genetic alterations is closely associated with the progression of myelodysplastic syndromes toward acute myeloid leukemia. OBJECTIVE: To investigate the pr...